Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $636.76 million. The enterprise value is $456.34 million.
| Market Cap | 636.76M |
| Enterprise Value | 456.34M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 120.03 million shares outstanding. The number of shares has increased by 17.29% in one year.
| Shares Outstanding | 120.03M |
| Shares Change (YoY) | +17.29% |
| Shares Change (QoQ) | +12.98% |
| Owned by Insiders (%) | 26.27% |
| Owned by Institutions (%) | 66.16% |
| Float | 51.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,077.43 |
| Forward PS | n/a |
| PB Ratio | 2.61 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 772.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.91, with a Debt / Equity ratio of 0.18.
| Current Ratio | 8.91 |
| Quick Ratio | n/a |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -100.90% and return on invested capital (ROIC) is -74.11%.
| Return on Equity (ROE) | -100.90% |
| Return on Assets (ROA) | -79.80% |
| Return on Capital (ROIC) | -74.11% |
| Revenue Per Employee | $2,526 |
| Profits Per Employee | -$873,919 |
| Employee Count | 234 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Prime Medicine has paid $57,000 in taxes.
| Income Tax | 57,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.61% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -64.61% |
| 50-Day Moving Average | 6.32 |
| 200-Day Moving Average | 7.00 |
| Relative Strength Index (RSI) | 42.95 |
| Average Volume (20 Days) | 1,033,061 |
Short Selling Information
The latest short interest is 12.71 million, so 10.59% of the outstanding shares have been sold short.
| Short Interest | 12.71M |
| Short Previous Month | 11.57M |
| Short % of Shares Out | 10.59% |
| Short % of Float | 24.57% |
| Short Ratio (days to cover) | 11.67 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $591,000 and -$204.50 million in losses. Loss per share was -$2.18.
| Revenue | 591,000 |
| Gross Profit | 591,000 |
| Operating Income | -213.10M |
| Pretax Income | -204.44M |
| Net Income | -204.50M |
| EBITDA | -186.22M |
| EBIT | -204.44M |
| Loss Per Share | -$2.18 |
Balance Sheet
The company has $224.22 million in cash and $43.79 million in debt, giving a net cash position of $180.43 million or $1.50 per share.
| Cash & Cash Equivalents | 224.22M |
| Total Debt | 43.79M |
| Net Cash | 180.43M |
| Net Cash Per Share | $1.50 |
| Equity (Book Value) | 243.77M |
| Book Value Per Share | 2.03 |
| Working Capital | 193.21M |
Cash Flow
In the last 12 months, operating cash flow was -$191.56 million and capital expenditures -$9.05 million, giving a free cash flow of -$200.61 million.
| Operating Cash Flow | -191.56M |
| Capital Expenditures | -9.05M |
| Free Cash Flow | -200.61M |
| FCF Per Share | -$1.92 |
Margins
Gross margin is 100.00%, with operating and profit margins of -36,057.53% and -34,601.86%.
| Gross Margin | 100.00% |
| Operating Margin | -36,057.53% |
| Pretax Margin | -34,592.22% |
| Profit Margin | -34,601.86% |
| EBITDA Margin | -31,509.14% |
| EBIT Margin | -34,592.22% |
| FCF Margin | -33,943.65% |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.29% |
| Shareholder Yield | -17.29% |
| Earnings Yield | -32.12% |
| FCF Yield | -31.50% |
Analyst Forecast
The average price target for Prime Medicine is $15.70, which is 195.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.70 |
| Price Target Difference | 195.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -11.75% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of 1.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 1 |